The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 486)
Abstract
An extremely ill patient, with Cushing's syndrome caused by an ACTH-secreting pituitary macroadenoma, experienced complications of end-stage cardiomyopathy, profound psychosis, and multiple metabolic disturbances. Initially treated unsuccessfully by a combination of conventional surgical, medical, and radiotherapeutic approaches, he responded dramatically to high-dose long-term mifepristone therapy (up to 25 mg/kg x d). Treatment efficacy was confirmed by the normalization of all biochemical glucocorticoid-sensitive measurements, as well as by the significant reversal of the patient's heart failure, the resolution of his psychotic depression, and the eventual unusual return of his adrenal axis to normal. His 18-month-long mifepristone treatment course was notable for development of severe hypokalemia that was attributed to excessive cortisol activation of the mineralocorticoid receptor, which responded to spironolactone administration. This case illustrates the efficacy of high-dose long-term treatment with mifepristone in refractory Cushing's syndrome. The case also demonstrates the potential need for concomitant mineralocorticoid receptor blockade in mifepristone-treated Cushing's disease, because cortisol levels may rise markedly, reflecting corticotroph disinhibition, to cause manifestations of mineralocorticoid excess.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628 · cited 1×
“These clinical effects may be attributable to abnormal overactivation of MR. In physiological settings, the enzyme 11-hydroxysteroid dehydrogenase (11HSD) converts cortisol, an avid GR- and MR-binding glucocorticoid, to its 11-keto analog (cortisone), a non-GR, non-MR-binding glucocorticoid ( 12 ).”
BackgroundRapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Self-citationDorn, L. D., Burgess, E. S., Friedman, T. C., Dubbert, B., Gold, P. W., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3834 · Cited by 260
Newer diagnostic techniques and problems in Cushing’s disease
Findling, J. W., & Raff, H. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70063-3 · Cited by 97
Cited by
MCEWEN, B. S. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1314.001 · Cited by 1,638
Mood disorders and allostatic load
McEwen, B. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00177-x · Cited by 1,135
Essex, M. J., Klein, M. H., Cho, E., & Kalin, N. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01553-6 · Cited by 698
Fleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
“A straightforward approach of blocking insidious effects of corticosteroid excess was first reported in studies where patients with Cushing’s syndrome were treated with RU486 (mifepristone), a nonpeptide antagonist at progesterone receptors and at GRs (Chu et al. 2001, Nieman et al. 1985, van der Lely et al. 1991).”
BackgroundInfluentialThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
The stress cascade and schizophrenia: Etiology and onset
Corcoran, C., Walker, E., Huot, R., Mittal, V., Tessner, K., Kestler, L., & Malaspina, D. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007038 · Cited by 439
“2000), and case reports indicate that there is a remission of psychosis in Cushing's disease with correction of the endogenous hypercortisolemia (Johnson 1975; van der Lely et al. 1991; Chu et al. 2001).”
BackgroundWüst, S., van Rossum, E. F. C., Federenko, I. S., Koper, J. W., Kumsta, R., & Hellhammer, D. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031148 · Cited by 348
An open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Cortisol and depression: three questions for psychiatry
Herbert, J. (2013) · Psychological Medicine · doi:10.1017/s0033291712000955 · Cited by 301
“Of note, a case of Cushing’s-induced psychosis responded to mifepristone (Chu et al. 2001), supporting the notion that corticoid-dependent forms of MDD might respond to GR blockade.”
BackgroundCushing’s Syndrome: important issues in diagnosis and management
Findling, J. W., & Raff, H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0997 · Cited by 294
Sheehan, J. P., Niranjan, A., Sheehan, J. M., Jane, J. A., Laws, E. R., Kondziolka, D., Flickinger, J., Landolt, A. M., Loeffler, J. S., & Lunsford, L. D. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.102.4.0678 · Cited by 262
de Kloet, E. R., DeRijk, R. H., & Meijer, O. C. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0403 · Cited by 193
Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease
Castinetti, F., Morange, I., Jaquet, P., Conte-Devolx, B., & Brue, T. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0514 · Cited by 175
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Nishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
“Moreover, increased cortisol levels can lead to severe hypokalemia and/or hypertension owing to excessive cortisol activation of the mineralocorticoid receptor, which responded to spironolactone administration [252].”
BackgroundRole of glucocorticoids in dopamine-related neuropsychiatric disorders
Craenenbroeck, K. V., Bosscher, K. D., Berghe, W. V., Vanhoenacker, P., & Haegeman, G. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.10.007 · Cited by 64
Simpson, G. M., Sheshai, A. E., Loza, N., Kingsbury, S. J., Fayek, M., Rady, A., & Fawzy, W. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0509 · Cited by 63
Block, T., Petrides, G., Kushner, H., Kalin, N., Belanoff, J., & Schatzberg, A. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000744 · Cited by 47
Self-citationBaroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., & Avogaro, A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0404-6 · Cited by 41
Metadata
- Authors
- Chu, J. W.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-08-01
- Volume
- 86
- Issue
- 8
- Pages
- 3568-3573
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W1994070278
- Cited by
- 200
- References
- 5
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.